<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04107194</url>
  </required_header>
  <id_info>
    <org_study_id>Policlinic Hospital 6, Bari</org_study_id>
    <nct_id>NCT04107194</nct_id>
  </id_info>
  <brief_title>Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.</brief_title>
  <acronym>THD-HP</acronym>
  <official_title>Comparison Between Tailored Therapy Guided by a Non-invasive Antibiotic Susceptibility Test and Empiric Treatment for First-line Helicobacter Pylori Eradication in Patients With Dyspepsia: a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bari</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study will be to assess in an open-label, multicenter, randomized controlled&#xD;
      trial whether a tailored therapy guided by a non-invasive antibiotic susceptibility test on&#xD;
      stool samples achieves higher Helicobacter eradication rates than an empiric antibiotic&#xD;
      regimen. For this purpose, consecutive patients with dyspeptic symptoms, diagnosis of&#xD;
      Helicobacter pylori infection and na√Øve to eradicating treatments will be allocated to either&#xD;
      of the two intervention arms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:&#xD;
&#xD;
      Eligible subjects will be defined by the positivity to at least 2 out of 4 tests for&#xD;
      Helicobacter pylori infection diagnosis (i.e. histology, rapid urease test, urea breath test&#xD;
      and serology). Stool samples and gastric biopsy specimens of eligible patients will be&#xD;
      analyzed at enrollment, using real time-polymerase chain reaction (RT-PCR) to detect&#xD;
      bacterial DNA mutations conferring resistance to amoxicillin, clarithromycin, tetracycline,&#xD;
      metronidazole, and levofloxacin. Participants allocated to the tailored intervention arm will&#xD;
      receive an antibiotic combination therapy according to the result of stool sample molecular&#xD;
      analysis. Participants allocated to the empiric intervention arm will be treated by either a&#xD;
      quadruple concomitant or bismuth-containing regimen, according to the 2017 European&#xD;
      Helicobacter pylori management guidelines. In all participants, infection eradication will be&#xD;
      evaluated 30 days after treatment end, using urea breath test. We will also assess the&#xD;
      diagnostic accuracy of the RT-PCR on fecal samples in detecting bacterial antibiotic&#xD;
      resistances, using the RT-PCR on gastric biopsy specimens as the reference standard.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2020</start_date>
  <completion_date type="Anticipated">April 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 14, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, multicenter, parallel-arm randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Investigators performing urea breath test 30 days after the end of the treatment (assessment of the primary outcome: eradication rate) will not be aware of participants' allocation and received therapy. Moreover, two independent investigators will perform RT-PCR on stool samples and gastric biopsy specimens, blinded to the other test results.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants achieving Helicobacter pylori eradication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>10 days</time_frame>
    <description>Any adverse event occurring during the 10-day treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants' compliance</measure>
    <time_frame>10 days</time_frame>
    <description>Number of assumed tablets divided by the total number of prescribed tablets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment withdrawal</measure>
    <time_frame>10 days</time_frame>
    <description>Withdrawal of any drug included in the prescribed regimen</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Diagnostic accuracy parameters</measure>
    <time_frame>30 days</time_frame>
    <description>Sensitivity, specificity, positive predictive value, negative predictive value, positive and negative likelihood ratio, and accuracy of the RT-PCR on fecal samples for the detection of antibiotic resistances</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">362</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <condition>Antibiotic Resistant Infection</condition>
  <condition>Antibiotic Resistant Strain</condition>
  <arm_group>
    <arm_group_label>Tailored therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clarithromycin-sensitive strain (10 day-therapy):&#xD;
Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)&#xD;
Clarithromycin-resistant and tetracycline-sensitive strain (10 day-therapy):&#xD;
Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)&#xD;
Clarithromycin- and tetracycline-resistant and levofloxacin-sensitive strain (10 day- therapy):&#xD;
Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Levofloxacin 500 mg bid (tablet)&#xD;
Clarithromycin-, tetracycline- and levofloxacin-resistant strain (10 day-therapy):&#xD;
Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Rifabutin 150 mg bid (tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empiric therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Either one of the two following 10-day regimens (according to physician's decision):&#xD;
Pantoprazole 40 mg bid (tablet) Amoxicillin 1000 mg bid (tablet) Clarithromycin 500 mg bid (tablet) Metronidazole 500 mg bid (tablet)&#xD;
Pantoprazole 40 mg bid (tablet) Tetracycline 125 mg + metronidazole 125 mg + bismuth 140 mg in a single tablet (3 tablets qid)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pantoprazole 40mg</intervention_name>
    <description>Proton pump inhibitor</description>
    <arm_group_label>Empiric therapy</arm_group_label>
    <arm_group_label>Tailored therapy</arm_group_label>
    <other_name>Pantorc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin 1000 MG</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>Empiric therapy</arm_group_label>
    <arm_group_label>Tailored therapy</arm_group_label>
    <other_name>Zimox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin 500mg</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>Empiric therapy</arm_group_label>
    <arm_group_label>Tailored therapy</arm_group_label>
    <other_name>Klacid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>Empiric therapy</arm_group_label>
    <arm_group_label>Tailored therapy</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline 125 MG</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>Empiric therapy</arm_group_label>
    <arm_group_label>Tailored therapy</arm_group_label>
    <other_name>Ambramicina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth Subcitrate</intervention_name>
    <description>Antibiotic adjuvant</description>
    <arm_group_label>Empiric therapy</arm_group_label>
    <arm_group_label>Tailored therapy</arm_group_label>
    <other_name>Denol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifabutin 150 MG</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>Tailored therapy</arm_group_label>
    <other_name>Mycobutin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin 500mg</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>Tailored therapy</arm_group_label>
    <other_name>Levoxacin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  presence of dyspeptic symptoms, according to Rome IV criteria;&#xD;
&#xD;
          -  Helicobacter pylori infection diagnosis by the positivity of at least 2 out of 4&#xD;
             diagnostic tests (i.e. histology, rapid urease test, urea breath test, and serology);&#xD;
&#xD;
          -  naive to Helicobacter pylori treatment;&#xD;
&#xD;
          -  written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous Helicobacter pylori treatment;&#xD;
&#xD;
          -  diagnosis of gastric cancer or other diseases requiring surgery;&#xD;
&#xD;
          -  contraindications to upper endoscopy;&#xD;
&#xD;
          -  chronic diarrhea;&#xD;
&#xD;
          -  known allergy to any drugs used in the intervention and control arm.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariabeatrice Principi, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bari</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michele Barone, Prof.</last_name>
    <phone>+39 3477157666</phone>
    <email>michele.barone@uniba.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Michele Barone</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Barone</last_name>
      <phone>3477157666</phone>
      <email>michele.barone@uniba.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.</citation>
    <PMID>27707777</PMID>
  </results_reference>
  <results_reference>
    <citation>Iannone A, Giorgio F, Russo F, Riezzo G, Girardi B, Pricci M, Palmer SC, Barone M, Principi M, Strippoli GF, Di Leo A, Ierardi E. New fecal test for non-invasive Helicobacter pylori detection: A diagnostic accuracy study. World J Gastroenterol. 2018 Jul 21;24(27):3021-3029. doi: 10.3748/wjg.v24.i27.3021.</citation>
    <PMID>30038469</PMID>
  </results_reference>
  <results_reference>
    <citation>Giorgio F, Ierardi E, Sorrentino C, Principi M, Barone M, Losurdo G, Iannone A, Giangaspero A, Monno R, Di Leo A. Helicobacter pylori DNA isolation in the stool: an essential pre-requisite for bacterial noninvasive molecular analysis. Scand J Gastroenterol. 2016 Dec;51(12):1429-1432. Epub 2016 Aug 9.</citation>
    <PMID>27687850</PMID>
  </results_reference>
  <results_reference>
    <citation>Drossman DA. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Feb 19. pii: S0016-5085(16)00223-7. doi: 10.1053/j.gastro.2016.02.032. [Epub ahead of print]</citation>
    <PMID>27144617</PMID>
  </results_reference>
  <results_reference>
    <citation>De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, Ierardi E, Zullo A. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010 Dec;19(4):409-14. Review.</citation>
    <PMID>21188333</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 25, 2019</study_first_submitted>
  <study_first_submitted_qc>September 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2019</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bari</investigator_affiliation>
    <investigator_full_name>Alfredo Di Leo</investigator_full_name>
    <investigator_title>Professor of University of Bari</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
    <mesh_term>Bismuth tripotassium dicitrate</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

